The Journal of pediatrics
-
The Journal of pediatrics · Dec 2008
Randomized Controlled Trial Multicenter StudyInfliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-alpha monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). ⋯ Both infliximab and a second IVIG infusion were safe and well tolerated in the subjects with KD who were resistant to standard IVIG treatment. The optimal management of patients resistant to IVIG remains to be determined.